About the MACULIGHT Study

The MACULIGHT study is a multicenter, prospective, randomized, and controlled clinical trial with 120 patients, conducted at leading German eye clinics. It investigates the efficacy and safety of photobiomodulation as a home therapy for patients with early and intermediate dry age-related macular degeneration.

The study is funded by the Federal Ministry for Research, Technology and Space Travel (BMFTR). The study is sponsored by Ciromed GmbH; scientific partners include the University Medical Center Schleswig-Holstein (UKSH), the University Eye Clinic Bochum at Knappschaftskrankenhaus, the MVZ Perfektes Sehen in Cologne, the Hauck-Rohrbach Eye Centers in Düsseldorf, and the Eye Center at St. Franziskus-Hospital Münster.

Study Centers & Partners

University Medical Center Schleswig-Holstein

University Hospital Knappschaftskrankenhaus Bochum

Eye Center at St. Franziskus-Hospital Münster

Study Goals & Benefits

Download MACULIGHT Patient Flyer (PDF)

Primary Study Goal

Evaluation of the efficacy and safety of PBM on best-corrected visual acuity (BCVA) and thus slowing the loss of vision with the medical device MACULIGHT®.

What are the potential benefits of MACULIGHT treatment for me?

Preservation of visual acuity

Slowing or even halting the progression of AMD

Less frequent progression to the late stage / wet AMD compared to the normal course of the disease

Avoidance of injections into the eye

Stabilization / positive change in vision in twilight

Scientific Article on the Study

Article in Ophthalmologische Nachrichten (Issue 10.2025)

Read now

The MACULIGHT Study at a Glance

Learn more about the BMFTR-funded clinical study on the efficacy of photobiomodulation for dry AMD in this expert lecture.

Video provided by MVZ Perfektes Sehen – Dr. Gerten & Colleagues, Cologne

Interested in the MACULIGHT® Study?

Find out if you are eligible to participate in the clinical study. Participation is free and supervised by experienced medical professionals.

The MACULIGHT® Therapy